-
71.发明公开公开(公告)号：US20230265158A1
公开(公告)日：2023-08-24
申请号：US18054566
申请日：2022-11-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , C12N9/64 , G01N33/566 , C12N5/0783 , C07K14/47 , G01N33/569 , C12Q1/6886 , A61K45/06 , A61K39/00 , A01N37/46 , A61K38/17 , C07K16/28 , A61K38/06 , C07K14/00 , C07K16/30 , A61K38/08 , C07K16/18 , G01N33/50 , C07K7/02 , C07K7/06 , C07K14/725 , A61K38/00
CPC classification number: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/30 , C07K16/2833 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/566 , G01N33/5088 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/47 , G01N2333/7051 , G01N2333/70503 , G01N2333/70539 , G01N2500/10
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号：US11730904B2
公开(公告)日：2023-08-22
申请号：US17338962
申请日：2021-06-04
Applicant: OptiNose AS
Inventor： Per Gisle Djupesland , Ramy A. Mahmoud , Ole A Andreassen , Lars T. Westlye , Daniel S. Quintana , Knut T. Smerud , Colin David Sheldrake
IPC: A61M15/08 , A61M15/00 , A61K38/22 , A61K38/28 , A61K38/095 , A61K38/08 , A61K9/00 , A61M29/00 , A61M11/00 , A61M31/00
CPC classification number: A61M15/08 , A61K9/0043 , A61K38/08 , A61K38/095 , A61K38/22 , A61K38/28 , A61M11/00 , A61M15/009 , A61M15/0013 , A61M15/0021 , A61M15/0098 , A61M29/00 , A61M31/00 , A61M2202/04 , A61M2202/064 , A61M2210/0618
Abstract: A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
-
公开(公告)号：US20230255873A1
公开(公告)日：2023-08-17
申请号：US18018412
申请日：2021-07-28
Applicant: Sederma
Inventor： Philippe Mondon , Caroline Ringenbach , Olga Gracioso
CPC classification number: A61K8/64 , A61Q19/08 , A61Q17/005 , A61K38/08 , A61P17/02
Abstract: The treatment according to the invention provides for the use of at least one peptide of general Formula X-(Xaa)nK*TSK*X′aa-(Xaa)mZ for a non-therapeutic cosmetic treatment of keratin materials of the skin and of its integuments, including treatment of the epidermis, scalp, hair, and nails, where X, Xaa, K*, X′aa, Z, m and n are as defined. A preferred peptide is Pal-KTSKS.
-
公开(公告)号：US20230248802A1
公开(公告)日：2023-08-10
申请号：US18014660
申请日：2021-06-23
Applicant: Matteo BORDIGNON , BELLA AURORA LABS, S.A.
Inventor： Matteo BORDIGNON , Sergi HERNANDEZ NAVARRO , Jordi SEGURA TEJEDOR
CPC classification number: A61K38/10 , A61P17/00 , A61P37/06 , A61K38/08 , A61K35/618 , A61K47/6923
Abstract: The present invention relates to a pharmaceutical composition for the treatment of vitiligo comprising the combination of a peptide which is an inhibitor of the melanoma inhibitory activity (MIA) protein and snail secretion. The invention also relates to a kit comprising this composition and a dietary supplement comprising an antioxidant. The invention also relates to the use of the composition or to the use of the kit comprising such composition for the prevention and/or treatment of vitiligo.
-
公开(公告)号：US11717556B2
公开(公告)日：2023-08-08
申请号：US17041926
申请日：2019-03-05
Applicant: NATIONAL CANCER CENTER
Inventor： Hyonchol Jang , Byung Il Lee , Hong-Duk Youn , Bomin Song
CPC classification number: A61K38/16 , A61K35/28 , A61K38/08 , A61K38/10 , A61K45/06 , A61P35/00 , G01N33/574
Abstract: The present invention relates to a stemness-suppressing composition comprising an OCT4 function-inhibiting peptide and, more particularly, to a composition comprising a peptide as an effective ingredient for suppressing the stemness of various stem cells such as general stem cells, cancer stem cells, and the like, wherein the peptide inhibits the function of OCT4 by inducing the phosphorylation of OCT4. OCT4 function-inhibiting peptides of the present invention are expected to find applications in various fields through the suppressive activity thereof against stemness of stem cells.
-
Patent Agency Ranking
76.发明公开公开(公告)号：US20230241110A1
公开(公告)日：2023-08-03
申请号：US18164418
申请日：2023-02-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11712462B2
公开(公告)日：2023-08-01
申请号：US17245213
申请日：2021-04-30
Applicant: REALTA HOLDINGS, LLC
Inventor： Neel K. Krishna , Kenji Cunnion
CPC classification number: A61K38/43 , A61K9/0019 , A61K38/005 , A61K38/08 , A61K47/10 , A61P37/06 , C07K14/005 , C07K14/4703 , C12N2770/00022 , C12N2770/00033
Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.
-
公开(公告)号：US20230235016A1
公开(公告)日：2023-07-27
申请号：US18052824
申请日：2022-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
CPC classification number: C07K14/70539 , A61K38/06 , C12N9/6491 , C12N5/0636 , C07K16/30 , C07K14/4748 , A61K39/0011 , C07K16/2833 , A61K45/06 , C07K14/001 , C07K7/06 , C07K7/02 , G01N33/505 , G01N33/566 , G01N33/5088 , A61K39/0005 , C07K16/18 , C07K14/47 , C12N5/0638 , A61K38/08 , C07K14/7051 , G01N33/56972 , C07K14/4702 , A61K38/1774 , C12Q1/6886 , G01N33/56977 , A01N37/46 , C07K2317/34 , C12Q2600/106 , C12Q2600/158 , G01N2333/7051 , A61K2039/54 , G01N2333/70539 , C07K2317/31 , C07K2317/24 , G01N2333/70503 , C07K2319/00 , C07K2319/40 , C12N2502/11 , A61K2039/572 , G01N2333/47 , C12N2501/998 , C12Y304/24 , A61K2039/57 , A61K2039/585 , A61K38/00
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
79.发明公开公开(公告)号：US20230233645A1
公开(公告)日：2023-07-27
申请号：US17947492
申请日：2022-09-19
Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventor： Gregory S. Hageman , Giuliana Silverstri , Paulina Haas , Monika Fleckenstein , Christian Matthew Pappas , Robin Guymer
IPC: A61K38/17 , C12Q1/6883 , A61K31/015 , A61K31/225 , A61K31/4422 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08
CPC classification number: A61K38/1709 , C12Q1/6883 , A61K31/015 , A61K31/225 , A61K31/4422 , A61K38/005 , A61K38/06 , A61K38/07 , A61K38/08 , A01K2217/052 , A01K2227/105 , A01K2267/03 , C12Q2600/156 , C12Q2600/112
Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.
-
80.发明公开公开(公告)号：US20230233612A1
公开(公告)日：2023-07-27
申请号：US18176678
申请日：2023-03-01
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
7087
records
(took 0.038 seconds)
